TradeLink Capital LLC purchased a new position in Zoetis Inc (NYSE:ZTS) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 2,900 shares of the company’s stock, valued at approximately $247,000. Zoetis makes up 1.2% of TradeLink Capital LLC’s portfolio, making the stock its 21st largest position.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Gables Capital Management Inc. purchased a new position in Zoetis in the first quarter worth about $109,000. Migdal Insurance & Financial Holdings Ltd. grew its position in Zoetis by 3,033.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock worth $120,000 after acquiring an additional 1,365 shares in the last quarter. Private Capital Group LLC grew its position in Zoetis by 118.4% in the first quarter. Private Capital Group LLC now owns 1,529 shares of the company’s stock worth $128,000 after acquiring an additional 829 shares in the last quarter. Mckinley Capital Management LLC Delaware purchased a new position in Zoetis in the first quarter worth about $134,000. Finally, Lenox Wealth Advisors LLC grew its position in Zoetis by 259.4% in the second quarter. Lenox Wealth Advisors LLC now owns 1,682 shares of the company’s stock worth $143,000 after acquiring an additional 1,214 shares in the last quarter. Institutional investors own 90.45% of the company’s stock.
Zoetis opened at $91.70 on Friday, MarketBeat reports. The company has a quick ratio of 2.92, a current ratio of 4.38 and a debt-to-equity ratio of 2.50. Zoetis Inc has a fifty-two week low of $59.64 and a fifty-two week high of $93.67. The company has a market cap of $44.52 billion, a PE ratio of 32.31, a P/E/G ratio of 1.90 and a beta of 1.02.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 4th. Stockholders of record on Friday, July 20th will be paid a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend is Thursday, July 19th. Zoetis’s dividend payout ratio is presently 20.83%.
In other news, insider Kristin C. Peck sold 5,000 shares of Zoetis stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $86.22, for a total transaction of $431,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $84.76, for a total transaction of $169,520.00. Following the sale, the insider now directly owns 22,023 shares of the company’s stock, valued at approximately $1,866,669.48. The disclosure for this sale can be found here. Insiders have sold 15,283 shares of company stock valued at $1,366,924 in the last ninety days. Insiders own 0.35% of the company’s stock.
Several research analysts recently commented on ZTS shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $98.00 price target on shares of Zoetis in a research report on Wednesday, May 16th. Craig Hallum reissued a “buy” rating and issued a $94.00 price objective (up previously from $87.00) on shares of Zoetis in a research note on Wednesday, April 25th. Bank of America raised their price objective on shares of Zoetis from $97.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. Jefferies Financial Group set a $96.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday, July 13th. Finally, Citigroup reissued a “buy” rating and issued a $98.00 price objective (up previously from $85.00) on shares of Zoetis in a research note on Thursday, April 19th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Zoetis presently has an average rating of “Buy” and a consensus target price of $89.64.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
See Also: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.